Day: September 8, 2024

MacroGenics to host investor call to review key data presented at ESMO on Monday, September 16, 2024, at 8:00 a.m. ET ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024. The following poster will be available on Sunday, September 15, 2024: TAMARACK: Randomized Phase 2 trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in...

BRISBANE, Australia, Sept. 09, 2024 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX”), a leading battery materials and technology company, today announced that the company is scheduled to participate in the following upcoming investor event in September 2024: H.C. Wainwright 26th Annual Global Investment Conference to be held in New York, NY on September 10th and 11th Presentation materials will be available prior to the event at the NOVONIX investor relations website. This announcement has been authorized for release by NOVONIX Chairman, Admiral Robert J. Natter, USN Ret. About NOVONIX NOVONIX is a leading battery technology company revolutionizing the global lithium-ion battery industry with innovative, sustainable technologies, high-performance materials, and more efficient production methods. The company...

Oslo, September 9, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data analysis from the UV1 Phase II NIPU trial (NCT04300244), at the 2024 ESMO Congress. The NIPU trial evaluated the addition of UV1 telomerase vaccine to immunotherapy with ipilimumab and nivolumab compared with ipilimumab and nivolumab alone, as a second-line treatment for patients with inoperable malignant pleural mesothelioma. As presented at ESMO 2023, the trial did not meet the primary endpoint of improved progression-free survival (PFS) by blinded, independent central review (BICR), however the data showed a meaningful benefit on the key secondary endpoints including a doubling of objective response rate (ORR) and a 27% reduction in risk...

Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the abstract sharing clinical data from its ongoing Phase 1 clinical trial of CFT1946, a novel BiDAC™ degrader, in mutant BRAF V600 solid tumors, was released in conjunction with the ESMO Congress 2024 scheduled for September 13 – 17, 2024 in Barcelona, Spain. The full abstract, which includes results with a data cut-off of April 12, 2024, can be accessed on the ESMO Congress 2024 website. Data on 36 patients, with a data cut-off...

        8 September 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announces that the company will present updated data from the Phase 1a trial of AVA6000 at the 2024 European Society for Medical Oncology (ESMO) Congress, in Barcelona, Spain from 13-17 September 2024. The poster presentation will be based on an updated data cut from the Phase 1a trial of AVA6000 in patients with Fibroblast Activation Protein (FAP)-positive solid tumours. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the...

Saint-Cloud, 8 September 2024 – Elis’ management opens tomorrow, Monday 9 September, a previously scheduled non-deal investor roadshow during which the company will discuss its business and strategy. As part of this two-week roadshow, Elis will host a webcast presentation and question-and-answer session for investors and analysts on Monday September 9 at 8:00am CET with Xavier Martiré, Chairman of the Management Board and Louis Guyot, Chief Financial Officer. The link to the webcast is: https://edge.media-server.com/mmc/p/a989hn6f The link to the conference call & Q&A session is: https://register.vevent.com/register/BIf265c1603840438ea31981add0686c9c A presentation will be available at 7:00am GMT (8:00am CET) on Elis’ corporate website at this address: https://fr.elis.com/en/group/investor-relations/regulated-information. About...

SAN DIEGO, Sept. 07, 2024 (GLOBE NEWSWIRE) — Embrace Change Acquisition Corp. (Nasdaq: EMCG, EMCGW, EMCGU, EMCGR) (“Embrace Change” or the “Company”), announced today that on September 5, 2024, it received an additional staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is delinquent in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”) and that this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. The failure to timely file the 10-Q is a violation of Nasdaq Listing Rule 5250(c)(1). Embrace Change is actively working to complete and file the delayed Form 10-Q. In accordance with the timeline established...